Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019550192> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2019550192 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCThe PI3K/AKT pathway is a key driver of cell growth, proliferation and survival, and deregulation at many levels of the pathway is observed in numerous cancers. Given the importance of PI3K/AKT signaling in cancer, a number of compounds targeting this pathway are currently in clinical development. Several AKT-targeted compounds, such as the ATP-competitive inhibitor AZD5363 and the allosteric inhibitor MK2206, have entered clinical trial. Whilst resistance to AKT inhibition has not yet been well defined, the development of acquired resistance has been a major barrier to the success of a number of molecularly targeted therapies, such as those which target V600E mutant BRAF. Identifying resistance mechanisms to AKT inhibition prior to the development of resistance in the clinic may assist in selecting patient populations and generating combination treatments to overcome resistance, potentially increasing the clinical utility of these inhibitors. The aims of this study were therefore to generate and characterize cell lines resistant to AKT inhibition.CCT129254, a precursor of AZD5363, is a novel ATP-competitive AKT inhibitor identified in a drug discovery program at The Institute of Cancer Research, London UK, in collaboration with Astex Therapeutics and AstraZeneca. CCT129254 is a potent and selective inhibitor of the three AKT isoforms (IC50 values between 13 and 66 nM), and treatment of cells with CCT129254 reduced phosphorylation of PRAS40, GSK3β and rpS6, downstream biomarkers of AKT activity. By exposing PTEN-deficient A2780 ovarian carcinoma cells to escalating doses of inhibitor, we have successfully generated a cell line with acquired resistance to CCT129254 (A2780 254R). We obtained approximately 4.8-fold resistance to CCT129254 in A2780 254R cells compared to parental A2780 (GI50: A2780 = 2.9 μM; A2780 254R = 14 μM). Interestingly, testing against a panel of signal transduction inhibitors revealed a 10-fold resistance to MK2206 in A2780 254R cells (GI50: A2780 = 0.30 μM; A2780 254R = 3.1 μM). Minimal cross-resistance was observed to the PI3K inhibitor GDC-0941 (1.9-fold, GI50: A2780 = 99 nM; A2780 254R = 185 nM), the mTORC1 inhibitor RAD001 (1.9-fold, GI50: A2780 = 1.65 nM; A2780 254R = 3.18 nM), and the dual PI3K/mTOR inhibitor PI-103 (1.7-fold, GI50: A2780 = 112 nM; A2780 254R = 188 nM). In addition, we have observed changes in PI3K/AKT pathway signaling biomarkers using western blot analysis. We have also utilized gene expression microarray analysis and exome sequencing to identify candidate genes involved in the resistance phenotype. We are currently validating potential resistance mechanisms identified in our candidate and global based approaches, and are investigating inhibitor combinations to overcome resistance.Citation Format: Denis T. Akan, Michael I. Walton, Michelle D. Garrett. Generation of an acquired resistance model to the novel AKT inhibitor CCT129254. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4447. doi:10.1158/1538-7445.AM2013-4447" @default.
- W2019550192 created "2016-06-24" @default.
- W2019550192 creator A5015193618 @default.
- W2019550192 creator A5060089081 @default.
- W2019550192 creator A5091648628 @default.
- W2019550192 date "2013-04-15" @default.
- W2019550192 modified "2023-09-25" @default.
- W2019550192 title "Abstract 4447: Generation of an acquired resistance model to the novel AKT inhibitor CCT129254." @default.
- W2019550192 doi "https://doi.org/10.1158/1538-7445.am2013-4447" @default.
- W2019550192 hasPublicationYear "2013" @default.
- W2019550192 type Work @default.
- W2019550192 sameAs 2019550192 @default.
- W2019550192 citedByCount "0" @default.
- W2019550192 crossrefType "proceedings-article" @default.
- W2019550192 hasAuthorship W2019550192A5015193618 @default.
- W2019550192 hasAuthorship W2019550192A5060089081 @default.
- W2019550192 hasAuthorship W2019550192A5091648628 @default.
- W2019550192 hasConcept C11960822 @default.
- W2019550192 hasConcept C121608353 @default.
- W2019550192 hasConcept C126322002 @default.
- W2019550192 hasConcept C154137905 @default.
- W2019550192 hasConcept C185592680 @default.
- W2019550192 hasConcept C2777609662 @default.
- W2019550192 hasConcept C2779707156 @default.
- W2019550192 hasConcept C502942594 @default.
- W2019550192 hasConcept C55493867 @default.
- W2019550192 hasConcept C62112901 @default.
- W2019550192 hasConcept C62478195 @default.
- W2019550192 hasConcept C71924100 @default.
- W2019550192 hasConcept C75217442 @default.
- W2019550192 hasConcept C86554907 @default.
- W2019550192 hasConcept C98274493 @default.
- W2019550192 hasConceptScore W2019550192C11960822 @default.
- W2019550192 hasConceptScore W2019550192C121608353 @default.
- W2019550192 hasConceptScore W2019550192C126322002 @default.
- W2019550192 hasConceptScore W2019550192C154137905 @default.
- W2019550192 hasConceptScore W2019550192C185592680 @default.
- W2019550192 hasConceptScore W2019550192C2777609662 @default.
- W2019550192 hasConceptScore W2019550192C2779707156 @default.
- W2019550192 hasConceptScore W2019550192C502942594 @default.
- W2019550192 hasConceptScore W2019550192C55493867 @default.
- W2019550192 hasConceptScore W2019550192C62112901 @default.
- W2019550192 hasConceptScore W2019550192C62478195 @default.
- W2019550192 hasConceptScore W2019550192C71924100 @default.
- W2019550192 hasConceptScore W2019550192C75217442 @default.
- W2019550192 hasConceptScore W2019550192C86554907 @default.
- W2019550192 hasConceptScore W2019550192C98274493 @default.
- W2019550192 hasLocation W20195501921 @default.
- W2019550192 hasOpenAccess W2019550192 @default.
- W2019550192 hasPrimaryLocation W20195501921 @default.
- W2019550192 hasRelatedWork W1965087096 @default.
- W2019550192 hasRelatedWork W1969001593 @default.
- W2019550192 hasRelatedWork W1973723861 @default.
- W2019550192 hasRelatedWork W2020287091 @default.
- W2019550192 hasRelatedWork W2027991451 @default.
- W2019550192 hasRelatedWork W2047774928 @default.
- W2019550192 hasRelatedWork W2052831589 @default.
- W2019550192 hasRelatedWork W2065576728 @default.
- W2019550192 hasRelatedWork W2067956232 @default.
- W2019550192 hasRelatedWork W2077928959 @default.
- W2019550192 hasRelatedWork W2095228707 @default.
- W2019550192 hasRelatedWork W2315514012 @default.
- W2019550192 hasRelatedWork W2316147969 @default.
- W2019550192 hasRelatedWork W2329334073 @default.
- W2019550192 hasRelatedWork W2330446675 @default.
- W2019550192 hasRelatedWork W2330637982 @default.
- W2019550192 hasRelatedWork W2342852175 @default.
- W2019550192 hasRelatedWork W2407580832 @default.
- W2019550192 hasRelatedWork W2564776454 @default.
- W2019550192 hasRelatedWork W2741082028 @default.
- W2019550192 isParatext "false" @default.
- W2019550192 isRetracted "false" @default.
- W2019550192 magId "2019550192" @default.
- W2019550192 workType "article" @default.